BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Jakobs TF, Hoffmann R, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubiensky A, Reiser MF, Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres. Eur Radiol 2007;17:1320-30. [DOI: 10.1007/s00330-006-0508-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
2 Jadlowiec CC, Heimbach JK. Advances in How We Prioritize Liver Allocation for Hepatocellular Carcinoma in the USA. Curr Transpl Rep 2016;3:334-40. [DOI: 10.1007/s40472-016-0127-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
4 Gray SH, White JA, Li P, Kilgore ML, Redden DT, Abdel Aal AK, Simpson HN, McGuire B, Eckhoff DE, Dubay DA. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy. J Vasc Interv Radiol 2017;28:231-237.e2. [PMID: 27939085 DOI: 10.1016/j.jvir.2016.09.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A; HOVAS Group (Hepatocellular Carcinoma Treatment Outcome at VA San Francisco). Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014;16:758-767. [PMID: 24467780 DOI: 10.1111/hpb.12214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
6 Giannini EG, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, Benvegnù L, Ludovico Rapaccini G, Farinati F, Zoli M. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:1378-1384. [PMID: 17059899 DOI: 10.1016/j.cgh.2006.08.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
7 Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005;42:358-64. [PMID: 15710218 DOI: 10.1016/j.jhep.2004.11.020] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
8 Lee YH, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Huo TI, Lee SD. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol. 2012;27:1581-1588. [PMID: 22497632 DOI: 10.1111/j.1440-1746.2012.07151.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lake-Bakaar G, Ahmed M, Evenson A, Bonder A, Faintuch S, Sundaram V. Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. Liver Cancer 2014;3:428-38. [PMID: 26280004 DOI: 10.1159/000343871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl 2016;22:178-87. [PMID: 26479422 DOI: 10.1002/lt.24360] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
11 Bryant MK, Dorn DP, Zarzour J, Smith JK, Redden DT, Saddekni S, Abdel Aal AK, Gray SH, Eckhoff DE, Dubay DA. Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB (Oxford). 2014;16:327-335. [PMID: 23980917 DOI: 10.1111/hpb.12149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
12 Kalva SP, Pectasides M, Liu R, Rachamreddy N, Surakanti S, Yeddula K, Ganguli S, Wicky S, Blaszkowsky LS, Zhu AX. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37:381-387. [PMID: 23754191 DOI: 10.1007/s00270-013-0654-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]